Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07513571 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults
A Phase 1 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07513571 is a Phase 1 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 32 participants.
The verdict
NCT07513571, a Phase 1 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.
Interventions
- DRUG AZD4954
- DRUG Laroprovstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-04-10 |
| Est. Completion | 2026-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07513571
The ClinicalTrials.gov registry entry for NCT07513571 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD4954 is the first listed.
NCT07513571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07513571 about?
NCT07513571 is a clinical study titled "A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults". The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.
What is the current status of trial NCT07513571?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-04-10. Estimated completion is 2026-07-09.
What interventions are being tested in trial NCT07513571?
The interventions under investigation include: AZD4954 (DRUG), Laroprovstat (DRUG).
Who is sponsoring clinical trial NCT07513571?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.